Latest news with #Suvannavejh
Business Insider
29-05-2025
- Business
- Business Insider
EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report) today and set a price target of $26.00. The company's shares closed today at $7.04. Confident Investing Starts Here: Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Verastem, and Apellis Pharmaceuticals. According to TipRanks, Suvannavejh has an average return of -9.0% and a 37.69% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for EyePoint Pharmaceuticals with a $31.57 average price target, a 348.44% upside from current levels. In a report released today, Scotiabank also reiterated a Buy rating on the stock with a $18.00 price target. Based on EyePoint Pharmaceuticals' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $24.45 million and a GAAP net loss of $45.2 million. In comparison, last year the company earned a revenue of $11.68 million and had a GAAP net loss of $29.28 million Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EYPT in relation to earlier this year. Earlier this month, Karen Zaderej, a Director at EYPT bought 10,000.00 shares for a total of $59,000.00.
Business Insider
23-05-2025
- Business
- Business Insider
Vigil Neuroscience Inc (VIGL) was downgraded to a Hold Rating at Mizuho Securities
Mizuho Securities analyst Graig Suvannavejh downgraded Vigil Neuroscience Inc (VIGL – Research Report) to a Hold yesterday and set a price target of $8.00. The company's shares closed yesterday at $7.88. Confident Investing Starts Here: According to TipRanks, Suvannavejh is an analyst with an average return of -11.9% and a 36.02% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Apellis Pharmaceuticals, and Harmony Biosciences Holdings. In addition to Mizuho Securities, Vigil Neuroscience Inc also received a Hold from William Blair's Myles Minter in a report issued yesterday. However, on the same day, Stifel Nicolaus maintained a Buy rating on Vigil Neuroscience Inc (NASDAQ: VIGL).
Business Insider
30-04-2025
- Business
- Business Insider
Mizuho Securities Reaffirms Their Buy Rating on Terns Pharmaceuticals (TERN)
In a report released today, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Terns Pharmaceuticals (TERN – Research Report), with a price target of $14.00. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Apellis Pharmaceuticals, and Insmed. According to TipRanks, Suvannavejh has an average return of -14.4% and a 35.05% success rate on recommended stocks. Currently, the analyst consensus on Terns Pharmaceuticals is a Strong Buy with an average price target of $18.00. Based on Terns Pharmaceuticals' latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $21.8 million. In comparison, last year the company earned a revenue of $1.32 million and had a GAAP net loss of $21.02 million
